- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharma
Conatus Pharmaceuticals Inc+ Add to Watchlist
CNAT:US7.7500 USD 0.9900 14.65%
As of 16:30:00 ET on 03/27/2015.
Company Profile for Conatus Pharmaceuticals Inc (CNAT)
Conatus Pharmaceuticals, Inc. develops therapeutics to treat liver disease. The Company offers drugs to control programmed cell death that contributes to a range of liver diseases and cancer treatments. Conatus Pharmaceuticals provides its products in the United States.
Conatus Pharmaceuticals Inc
Key Executives for Conatus Pharmaceuticals Inc (CNAT)
|Steven J MentoPresident/CEO/Co-Founder||Charles J CashionSenior VP:Finance/CFO/Secy|
|Gary Craig BurgessSenior VP:Clinical/Chief Medical Ofcr||Alfred P SpadaSenior VP:R&D/Chief Scientific Ofcr|
|Daniel L Ripley "Dan"Senior Dir/Head:Corporate Dev|